Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, S. -A. | - |
dc.contributor.author | Gennari, A. | - |
dc.contributor.author | Park, Y. H. | - |
dc.contributor.author | Kim, J. H. | - |
dc.contributor.author | Jiang, Z. -F. | - |
dc.contributor.author | Gupta, S. | - |
dc.contributor.author | Fadjari, T. H. | - |
dc.contributor.author | Tamura, K. | - |
dc.contributor.author | Mastura, M. Y. | - |
dc.contributor.author | Abesamis-Tiambeng, M. L. T. | - |
dc.contributor.author | Lim, E. H. | - |
dc.contributor.author | Lin, C. -H. | - |
dc.contributor.author | Sookprasert, A. | - |
dc.contributor.author | Parinyanitikul, N. | - |
dc.contributor.author | Tseng, L. -M. | - |
dc.contributor.author | Lee, S. -C. | - |
dc.contributor.author | Caguioa, P. | - |
dc.contributor.author | Singh, M. | - |
dc.contributor.author | Naito, Y. | - |
dc.contributor.author | Hukom, R. A. | - |
dc.contributor.author | Smruti, B. K. | - |
dc.contributor.author | Wang, S. -S. | - |
dc.contributor.author | Kim, S. B. | - |
dc.contributor.author | Lee, K. -H. | - |
dc.contributor.author | Ahn, H. K. | - |
dc.contributor.author | Peters, S. | - |
dc.contributor.author | Kim, T. W. | - |
dc.contributor.author | Yoshino, T. | - |
dc.contributor.author | Pentheroudakis, G. | - |
dc.contributor.author | Curigliano, G. | - |
dc.contributor.author | Harbeck, N. | - |
dc.date.accessioned | 2023-08-25T07:40:58Z | - |
dc.date.available | 2023-08-25T07:40:58Z | - |
dc.date.created | 2023-08-25 | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 2059-7029 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88840 | - |
dc.description.abstract | The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | ESMO OPEN | - |
dc.title | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 001044740800001 | - |
dc.identifier.doi | 10.1016/j.esmoop.2023.101541 | - |
dc.identifier.bibliographicCitation | ESMO OPEN, v.8, no.3 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85159041839 | - |
dc.citation.title | ESMO OPEN | - |
dc.citation.volume | 8 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Ahn, H. K. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | ESMO | - |
dc.subject.keywordAuthor | guidelines | - |
dc.subject.keywordAuthor | Pan-Asian | - |
dc.subject.keywordAuthor | metastatic breast cancer | - |
dc.subject.keywordAuthor | treatment | - |
dc.subject.keywordPlus | ALPELISIB PLUS FULVESTRANT | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SACITUZUMAB GOVITECAN | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | TRASTUZUMAB DERUXTECAN | - |
dc.subject.keywordPlus | REPORTED OUTCOMES | - |
dc.subject.keywordPlus | BRAIN METASTASIS | - |
dc.subject.keywordPlus | FINAL ANALYSIS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.